Our results suggest that CDK7i may be of most benefit if used before patients have received multiple lines of chemotherapy, as tumours with acquired resistance to other therapeutics may have upregulated ABC-transporters, and so may also be cross-resistant to CDK7i. Here, ABCG2 is linked to neoplasm.